The evaluation of the effect of keishibukuryogan on blood stagnation

The evaluation of the effect of keishibukuryogan on blood stagnation - The evaluation of the effect of keishibukuryogan on blood stagnation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021451

Enrollment

Registered

2016-03-14

Start date

2016-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood stagnation

Interventions

The administration of keishibukuryougan for 28 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The score of blood stagnation is over 20. No subjective symptom, drinking three times or less a week, and normal liver and renal function that has been confirmed in a medical examination within one year.

Exclusion criteria

Exclusion criteria: Any of the following: currently receiving a drug therapy, currently pregnant, and having and a history of anaphyraxy to keishibukuryogan.

Design outcomes

Primary

Measure	Time frame
The change of platelet aggregation between before, 2, 4, and 8 weeks after keishibukuryougan administration	—

Secondary

Measure	Time frame
The change of platelet function between before , 2, 4, and 8 weeks after keishibukuryougan administration	—

Countries

Japan

Contacts

Public ContactKeiko Ogawa

Kanazawa University Hospital Department of Kampo Medicine

okeiko@med.kanazawa-u.ac.jp076-265-2918

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026